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Abstract 
Naproxen suffers from general side effects of NSAIDs, owing to the presence of free carboxylic group.  
The study was aimed to retard the adverse effects of gastrointestinal origin. New series of 4-thiozolidinones 
derivatives of naproxen were synthesized Va-f. The structures of synthesized compounds have been established 
on the basis of their spectral FT-IR and 
1
H NMR data. In vivo acute anti-inflammatory effects of the synthesized 
compounds were evaluated in rats using egg-white induced edema model of inflammation. The tested 
compounds and the reference drug produced significant reduction of paw edema with respect to the effect of 
propylene glycol 50%v/v (control group). Compounds Va-e exhibited potent anti-inflammatory effect than 
naproxen (50mg/kg, i.p.) at 180-240 min., while compound Vf exhibited lower anti-inflammatory effect. 
Keywords: Naproxen, 4-Thiazolidinone, Anti-inflammatory activity.  
 
1. Introduction 
Non-steroidal anti-inflammatory drugs (NSAIDs) are used to treat a wide variety of illnesses and diseases, 
including inflammation, cancers, diabetes (insulin-resistant and related metabolic syndrome); and diseases of the 
peripheral and central nervous system, e.g., Alzheimer’s and Parkinson’s (Zhou et al.2010; Sobolewski et 
al.2010; Hiroki et al.2007; Laura et al. 2004). The therapeutic effect of NSAIDs derives from their ability to 
inhibit PG production. The first enzyme in the PG synthetic pathway is COX. This enzyme converts arachidonic 
acid AA to the unstable intermediates PGG2 and PGH2   and leads to the production of prostanoids, TXA2, and 
variety of PGs; these prostanoids have a variety of physiological functions and are also believed to be 
responsible for causing pain and swelling in inflammatory conditions (Laurence 2011).The three isotypes of 
COX (COX-1, COX-2 and COX-3) have been identified (Chandrasekharan et al.2002). COX-1 is a constitutive 
isoform found in most normal cells and tissues (Seibert et al. 1997). It is stimulated by growth factor and 
hormones and it has been called the housekeeping enzyme (Paloucek et al. 2001). The COX-1 plays fundamental 
roles in the generation of PGs in homoeostasis, and several other physiological functions including gastric 
protection and control of renal blood flow (Katzung 2013; Claus et al.2005).  
COX-2 is highly induced in settings of inflammation by cytokines and inflammatory mediators or 
physiological stress (Lipsky
 
et al.
 
2000). The prostaglandins (PGs) produced by COX-2 play a major role in 
inflammatory reactions and are responsible for the characteristic inflammatory symptoms (redness, pain, edema, 
fever and loss of function). The inducible isoform has also been implicated in pathological processes such as 
various cancer types (colorectal, breast), Alzheimer and Parkinson’s diseases
 
(Marnett et al.
 
2002).COX-3 is a 
recently identified splice variant/isoenzyme of COX-1 and, more suitably, may have been named COX-1b. In 
humans COX-3 mRNA is found in highest concentrations in the brain and heart (Chen et al.2008). The 
importance of COX-3 is that it could explain the pharmacological actions of paracetamol and other 
antipyretic/analgesic drugs which are weak inhibitors of COX-1 and COX-2, but penetrate easily into the central 
nervous system (Regina et al. 2005).Selective COX-2 inhibitors differ from traditional NSAIDs in two major 
ways; Coxibs are less likely to result in NSAID-induced gastropathy, and they do not inhibit platelet function 
(Bruce 2002). As a result, selective COX-2 inhibitors elicit less clinically significant GI damage and bleeding 
than conventional NSAIDs (Schnitzer et al.2004). 
There are numerous biologically active molecules which contain various heteroatoms such as nitrogen, 
sulphur and oxygen, always drawn the attention of chemist over the years mainly because of their biological 
importance. Thiazolidinones are thiazolidine derivatives and have an atom of sulfur at position 1, an atom of 
nitrogen at position 3 and a carbonyl group at position 2, 4, or 5(Verma et al.2008). 
The 4-thiazolidinone scaffold is very versatile and has featured in a number of clinically used drugs. 
They have found uses as anti-bacterial, anti-tubercular, anti-inflammatory, anti-convulsant, anti-cancer and anti-
viral agents, especially as anti-HIV agents (Handan et al.2005; Chen et al. 2010; Chandra et al. 2009; Srivastava 
et al. 2000; Danylo et al.2011; Rawal et al.2008). A series of thiazolidine-4-one derivatives from sulfanilamide 
were evaluated for anti-inflammatory, analgesic and anti-ulcer activity. The compound (1) and compound (2) 
with substitution R'-CH3 showed potential activity (Taranalli et al.2009).Compound (3), a thiazolidinone 
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derivative, which show interesting stereo selective anti-inflammatory/analgesic activities and might 
preferentially interact with inducible COX-2 isoform (Ottana et al. 2002).  Absence of 5-arylmethylidene moiety 
in compound (4) enhanced its anti-inflammatory activity and decreased the analgesic activity (Ali et al. 2007).as 
shown in Figure 1. Therefore, a group of 4-thiazolidinone pharmacophore derivatives incorporated in the 
carboxylate group of a naproxen were designed, synthesized and evaluated as anti-inflammatory agents with 
expected inhibitory selectivity towards COX-2 enzyme (Flower2003). 
 
 
Figure 1. Examples of anti-inflammatory thiazolidinone derivatives 
 
2. Experimental 
2.1. General 
Electro thermal melting point apparatus and open capillary tubes were used to determine the melting points and 
are uncorrected. Thin layer chromatography was run on TLC silica gel (60) F254, Merck (Germany), for checking 
the purity of the products as well as monitoring the progress of the reaction. Chromatograms were eluted by 
using two different solvent systems: A: Methanol: Acetic acid: Ether: Benzene (02:18:60: 20). B: Chloroform: 
Methanol (85:15). Compounds were revealed upon irradiation with UV light. IR spectra were recorded on a 
FTIR, Shimadzu 8100s spectrometer.
1
HNMR spectra were recorded on Bruker 500 MHz-Avanc III. 
 
2.2 Typical procedure for the reactions 
The synthesis of target compounds (I-Va-f) was achieved following procedures illustrated in Scheme 1. 
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Scheme 1. Synthesis of the target compounds (I-Va-f) 
2.2.1. Synthesis of ethyl 2-aminoacetate hydrochloride (I): 
Thionyl chloride (0.8 mL, 11 mmol) was added gradually to absolute ethanol (10 mL), cooled to (0°C). 2-
Aminoacetic acid (0.75 g, 10 mmol) was suspended in the reaction mixture and subjected to ultra-sonication at 
room temperature for (45 min.). On completion of the reaction, the solvent was removed under reduced pressure 
and the residue was purified by recrystallization from methanol: diethyl ether.  
The percent yield, physical data and Rf values are given in Table (2). FTIR: 1748cm
-1
 (C=O ester) and 1250cm
-1
 
(C-O-C ester). 
2.2.2. Synthesis of (s)-ethyl-2-[2-(6-methoxynaphthalen-2-yl)-propanamido] acetate (II): 
Compound (I) (2.8 g, 20 mmol), triethylamine (3 mL, 21 mmol) and Naproxen (4.6 g, 20 mmol) were dissolved 
in dry DCM (40 mL). The reaction mixture was stirred at (0
°
C) for (30 min.). To this solution (4.21 g, 20 mmol) 
DCC in dry DCM (10 mL) was added slowly in a drop wise manner. Reaction mixture was stirred for 3 days at 
(0°C). Precipitated DCU was filtered off and the solvent was distilled off under reduced pressure. The product 
obtained was dissolved in ethyl acetate (30mL) and filtered. Ethyl acetate layer was washed with 10% aqueous 
solution of sodium bicarbonate (3x30mL) and distilled water (3x30mL). Ethyl acetate layer was dried over 
anhydrous magnesium sulphate and filtered to get a clear solution of product in ethyl acetate. Solvent was 
evaporated under reduced pressure and the crude product was recrystallized by using hexane: ethyl acetate. 
The percent yield, physical data and Rf values are given in Table (2). FTIR: 3293cm
-1
 (NH amid); 
1740cm
-1
(C=O ester) and 1649cm
-1 
(C=O amide). 
1
H NMR (500 MHz, CDCl3: DMSO-d6) H: 1.14( 3H, t,  CH3 
ester);  1.42-1.43 (3H, d, CH3 naproxen); 3.80-3.84 (3H, m, CH naproxen and CH2 glycine); 3.87 (3H,  s, -OCH3 
naproxen); 4.04-4.08 (2H, q, CH2 ester); 7.14-7.79 (6H, m, naphthalene CH) and 8.40(1H, br.s, NH amide). 
2.2.3. Synthesis of (s)-N-(2-hydrazinyl-2-oxoethyl)-2-(6-methoxy-naphthalen-2-yl) propanamide (III): 
Compound (II) (1 g, 3 mmol) was dissolved in (15 mL) methanol and (0.7 mL, 14mmol) of hydrazine hydrate 
(90%) was added. The reaction mixture was stirred at r.t. overnight. On the next day the solvent was removed 
under reduced pressure and the crude product was washed with diethyl ether under stirring to afford the product 
Journal of Natural Sciences Research                                                                                                                                                www.iiste.org 
ISSN 2224-3186 (Paper)   ISSN 2225-0921 (Online) 
Vol.5, No.6, 2015 
 
24 
in pure state. 
The percent yield, physical data and Rf values are given in Table (2). FTIR: 3339 and 3277cm
-1
(NHNH2); 
1678cm
-1 
(C=O amidic); 1645cm
-1 
(C=O amide). 
1
H NMR (500 MHz, CDCl3: DMSO-d6) H:  4.20 (2H, br.s, 
NH2 hydrazide); 8.20 (1H, br.s, NH amide) and 9.01 (1H, s, NH hydrazide) . 
2.2.4. Synthesis of (s)-2-(6-methoxynaphthalen-2-yl)-N-(2-(2-(4-benzylidene) hydrazinyl)-2-oxoethyl) 
propanamide (IVa-f): 
Compound (III) (0.3 g, 1 mmol) and (1.1mmol) appropriate aromatic aldehydes (a-f) listed in Table (1) in 
absolute ethanol (25mL) were heated under reflux on a water bath for 4(hrs.), during the refluxing period (2-3) 
drops of glacial acetic acid were added. The solvent was distilled off under reduced pressure to a possible extent 
and residue was poured into ice cooled water to get the product. It was filtered, washed with cold water and dried. 
The crude product was purified by recrystallization from ethanol.  
The percent yield, physical data and Rf values are given in Table (2). 
(s)-2-(6-methoxynaphthalen-2-yl)-N-(2-(2-(4-benzylidene) hydrazinyl)-2-oxoethyl) propanamide (IVa):  
FTIR: 3291cm
-1
(NH amide); 1686 cm
-1
 (C=O amidic) and 1643 cm
-1
 (C=O amide & C=N). 
1
H NMR (500 MHz, 
CDCl3: DMSO-d6) H:  8.18 (1H, br.s, NH amide); 8.36 (1H, s, NH -N) and 11.41 (1H, s, NH =CH-Ar). 
(s)-2-(6-methoxynaphthalen-2-yl)-N-(2-(2-(4-chlorobenzylidene) hydrazinyl)-2-oxoethyl)propanamide (IVb): 
FTIR: 3293cm
-1
(NH amide); 1684 cm
-1
 (C=O amidic); 1645 cm
-1
 (C=O amide & C=N) and 1092 cm
-1
 (C-Cl). 
(s)-2-(6-methoxynaphthalen-2-yl)-N-(2-(2-(4-nitrobenzylidene )hydrazinyl)-2-oxoethyl) propanamide (IVc): 
FTIR: 3314cm
-1
(NH amide); 1690 cm
-1
 (C=O amidic); 1643 cm
-1
 (C=O amide & C=N); 1524 cm
-1
 (NO2 
asymmetric); 1343 cm
-1
 (NO2 symmetric). 
(s)-2-(6-methoxynaphthalen-2-yl)-N-(2-(2-(4-hydroxybenzylidene)hydrazinyl)-2-oxoethyl)propanamide(IVd): 
FTIR: 3362cm
-1
(OH); 3271cm
-1
(NH amide); 1686 cm
-1
 (C=O amidic) and 1656 cm
-1
 (C=O amide & C=N). 
(s)-2-(6-methoxynaphthalen-2-yl)-N-(2-(2-(4-methoxybenzylidene)hydrazinyl)-2-oxoethyl) propanamide (IVe): 
FTIR: 3306cm
-1
(NH amide); 1682 cm
-1
(C=O amidic); 1643 cm
-1
 (C=O amide & C=N) and 1254cm
-1
(OCH3). 
(s)-2-(6-methoxynaphthalen-2-yl)-N-(2-(2-(4-dimethyaminobenzylidene)hydrazinyl)-2-oxoethyl)propanamide (IVf):  
FTIR: 3319cm
-1
(NH amide); 1680cm
-1
(C=O amidic); 1643 cm
-1
 (C=O amide & C=N) and 1362cm
-1
(N(CH3)2).  
 
Table 1. Aromatic aldehyde’s name and products no. 
No. Aromatic Aldehyde’s name Product No. R Quantity(gm) 
a Benzaldehyde IVa H 0.116 
b 4-Chlorobenzaldehyde IVb Cl 0.154 
c 4-Nitrobenzaldehyde IVc NO2 0.166 
d 4-Hydroxybenzaldehyde IVd OH 0.134 
e 4-methoxybenzaldehyde IVe OCH3 0.149 
f 4-dimethylaminobenzaldehyde IVf N(CH3)2 0.164 
2.2.5. Synthesis of (s)-2-(6-methoxynaphthalen-2-yl)-N-(2-((2-(4-aryl)-4-oxothiazolidin-3-yl amino)-2-oxoethyl) 
propanamide (Va-f) : 
A mixture of Thioglycolic acid (3 mL) and (1 mmol) of either compound (IVa-f) were heated at (60°C) until 
reaction was complete about (3hrs.). Ethyl acetate (5mL) was added to the reaction mixture; the organic layer 
was washed with saturated sodium bicarbonate (3x20mL) and water (10mL), dried with anhydrous magnesium 
sulfate, and concentrated to give oil. The oil washed with diethyl ether to give the final compounds (Va-f). The 
percent yield, physical data and Rf values are given in Table (2). 
(s)-2-(6-methoxynaphthalen-2-yl)-N-(2-((2-(4-phenyl)-4-oxothiazolidin-3-yl)amino)-2-oxoethyl)propanamide 
(Va):  
FTIR: 3306cm
-1
(NH amide); 1726cm
-1
(C=O thiazolidinone); 1680cm
-1
 (C=O amidic) and 1655cm
-1
(C=O amide); 
1215cm
-1
(C-S). 
1
H NMR (500 MHz, CDCl3: DMSO-d6) H:  3.61-3.66 (2H, dd, CH2 thiazolidinone); 5.76 (1H, s, 
N-CH -S); 7.14-7.78 (11H, m, naphthalene and aromatic CH); 8.26 (1H, br. s, NH amide) and 10.21 (1H, s, NH -
N). 
(s)-2-(6-methoxynaphthalen-2-yl)-N-(2-((2-(4-chlorophenyl)-4-oxothiazolidin-3-yl)amino)-2-oxoethyl) 
propanamide(Vb):  
FTIR:  3324cm
-1
(NH amide); 1728cm
-1
(C=O thiazolidinone); 1684cm
-1
 (C=O amidic), 1655cm
-1
(C=O amide); 
1213cm
-1
(C-S); 1088cm
-1
(C-Cl). 
1
H NMR (500 MHz, CDCl3: DMSO-d6) H:  3.67-3.68 (2H, dd, CH2 
thiazolidinone); 5.77 (1H, s, N-CH -S); 7.13-7.79 (10H, m, naphthalene and aromatic CH); 8.24 (1H, br. s, NH 
amide) 10.20 (1H, s, NH -N). 
(s)-2-(6-methoxynaphthalen-2-yl)-N-(2-((2-(4-nitrophenyl)-4-oxothiazolidin-3-yl)amino)-2-oxoethyl) 
propanamide(Vc): 
 FTIR: 3277cm
-1
(NH amide); 1732cm
-1
(C=O thiazolidinone); 1690cm
-1
 (C=O amidic), 1661cm
-1
(C=O amide); 
1524 cm
-1
 (NO2 asymmetric); 1346 cm
-1
 (NO2 symmetric) and 1213cm
-1
(C-S). 
1
H NMR (500 MHz, CDCl3: 
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DMSO-d6) H:  3.62-3.67 (2H, dd, CH2 thiazolidinone); 5.92 (1H, s, N-CH -S); 7.13-7.78 (10H, m, naphthalene 
and aromatic CH); 8.24 (1H, br. s, NH amide) and 10.20 (1H, s, NH -N). 
(s)-2-(6-methoxynaphthalen-2-yl)-N-(2-((2-(4-hydroxyphenyl)-4-oxothiazolidin-3-yl)amino)-2-oxoethyl) 
propanamide(Vd):  
FTIR: 3308cm
-1
(OH); 3181cm
-1
(NH amide); 1717cm
-1
(C=O thiazolidinone); 1697cm
-1
 (C=O amidic), 1649cm
-
1
(C=O amide) and 1211cm
-1
(C-S). 
1
H NMR (500 MHz, CDCl3: DMSO-d6) 
1
H NMR (500 MHz, CDCl3: DMSO-
d6) H:  3.68-3.71 (2H, dd, CH2 thiazolidinone); 5.74 (1H, s, N-CH -S); 7.13-7.79 (10H, m, naphthalene and 
aromatic CH); 8.29 (1H, br.s, NH amide); 9.90 (1H, br.s, OH) and 10.00 (1H, s, NH -N). 
(s)-2-(6-methoxynaphthalen-2-yl)-N-(2-((2-(4-methoxyphenyl)-4-oxothiazolidin-3-yl)amino)-2-oxoethyl) 
propanamide(Ve):  
FTIR: 3310cm
-1
(NH amide); 1715cm
-1
(C=O thiazolidinone); 1697cm
-1
 (C=O amidic), 1649cm
-1
(C=O amide); 
1267cm
-1
(-OCH3) and 1213cm
-1
(C-S). 
1
H NMR (500 MHz, CDCl3: DMSO-d6) H:  3.68-3.71 (2H, dd, CH2 
thiazolidinone); 5.90 (1H, s, N-CH -S); 7.05-7.79 (10H, m, naphthalene and aromatic CH); 8.28 (1H, br. s, NH 
amide) and 10.04 (1H, s, NH -N). 
(s)-2-(6-methoxynaphthalen-2-yl)-N-(2-((2-(4-dimethylaminophenyl)-4-oxothiazolidin-3-yl)amino)-2-oxoethyl) 
propanamide(Vf):  
FTIR: 3310cm
-1
(NH amide); 1720cm
-1
(C=O thiazolidinone); 1699cm
-1
 (C=O amidic), 1649cm
-1
(C=O amide); 
1390cm
-1
(N(CH3)2); 1213cm
-1
(C-S). 
1
H NMR (500 MHz, CDCl3: DMSO-d6) H:  3.65-3.69 (2H, dd, CH2 
thiazolidinone); 5.73 (1H, s, N-CH -S); 6.66 (6H, s, N(CH3)2); 7.13-7.79 (10H, m, naphthalene and aromatic 
CH); 8.27 (1H, br.s, NH amide) and 9.50 (1H, s, NH -N). 
Table 2. The characterization and physical parameters of the target compounds and their intermediates 
No. Molecular Formula 
Molecular 
Weight 
Description %  yield Melting point (°C) 
 
Rf 
I C4H10NO2Cl 139 White crystals 90 145-147 
A=0.70 
B=0.48 
II C18H21NO4 315 Off white powder 65 84-86 
A=0.92 
B=0.55 
III C16H19N33 301 Yellow powder 78 158-160 
A=0.80 
B=0.51 
Iva C23H23N3O3 389 white fluffy powder 70 211-213 
A=0.65 
B=0.70 
IVb C23H22N3O3Cl 424 white fluffy powder 71 188-190 
A=0.51 
B=0.68 
IVc C23H22N4O5 434 Yellow fluffy powder 78 180-182 
A=0.45 
B=0.60 
IVd C23H23N3O4 405 White fluffy powder 68 227-229 
A=0.28 
B=0.42 
IVe C24H25N3O4 419 White fluffy powder 74 177-179 
A=0.22 
B=0.35 
IVf C25H28N4O3 432 yellow fluffy powder 69 190-192 
A=0.52 
B=0.44 
Va C25H25N3O4S 463 Off white powder 65 118-120 
A=0.76 
B=0.62 
Vb C25H24N3O4SCl 498 Off white powder 62 109-111 
A=0.88 
B=0.57 
Vc C25H24N4O6S 508 Yellow powder 68 134-136 
A=0.92 
B=0.68 
Vd C25H25N3O5S 479 White powder 61 188-190 
A=0.71 
B=0.53 
Ve C26H27N3O5S 493 White powder 63 186-188 
A=0.82 
B=0.48 
Vf C27H30N4O4S 506 Yellow powder 65 185-187 
A=0.91 
B=0.64 
Nap. C14H14O3 230 White powder - 157-158 
A=0.95 
B=0.11 
Gly. C2H5NO2 75 White powder - 233-234 
 A=0.98 
B=0.38 
 
3. Preliminary Pharmacological Studies 
3.1. Anti-inflammatory Evaluation Study 
In vivo acute anti-inflammatory effects of the chemically synthesized compounds (Va-f) were evaluated in egg-
white induced paw edema. Their evaluation for their ant-inflammatory activity based on measuring the decreases 
Journal of Natural Sciences Research                                                                                                                                                www.iiste.org 
ISSN 2224-3186 (Paper)   ISSN 2225-0921 (Online) 
Vol.5, No.6, 2015 
 
26 
of paw thickness. 
3.1.1. Methods 
A. Animals 
Albino rats of either sex weighing (170 ± 10 gm) were supplied by Iraqi center for cancer and medical genetic 
research and were housed in college of pharmacy- AL-Mustansiriya University under standardized conditions for 
10 days for acclimatization. Animals were fed commercial chaw and had free access to water ad libitum. 
Animals were brought to the laboratory, one hour before the experiment, and were divided into eight groups 
(each group consist of 6 rats) as follows: 
Group A: six rats served as control and treated with the vehicle (propylene glycol 50% v/v). 
Group B: six rats treated with (s)-naproxen as reference substance in a dose of 50mg/kg dissolved in Propylene 
glycol. 
Group C-H: six rats /group treated with the tested compounds (Va-f) respectively in doses that determined below, 
also dissolved in propylene glycol. 
B. Calculations for Dose Determination 
M.Wt. of (s)-Naproxen = 230.26 
50mg/kg /230.26 = Dose / M.Wt. of the tested compound. 
Table 3. Compounds with their molecular weight and dose 
Compounds Molecular Weight Dose mg/ kg 
(S)-Naproxen 230 50 
Va 463 101 
Vb 498 108 
Vc 508 110 
Vd 479 104 
Ve 493 107 
Vf 506 110 
C. Experimental Design 
The anti-inflammatory activity of the tested compounds was studied using the egg-white induced edema model. 
The paw thickness was measured by vernea at seven time intervals (0, 30, 60, 120, 180, 240, and 300 min) after 
drug administration. Acute inflammation was produced by a subcutaneous injection of (0.05 ml) of  undiluted 
egg-white into the plantar side of the left hind paw of the rats; 30 min after intra-peritoneal administration of the 
drugs or their vehicle.  
3.1.2. Statistical Analysis 
The data was expressed as the mean ± SEM and results were analyzed for statistical significance using student t-
test (Two Sample Assuming Equal Variances) for comparison between mean values. While comparisons 
between different groups were made using ANOVA: Two factors without replication. Probability (P) value of 
less than 0.05 was considered significant. 
 
4.Result and Descussions 
The anti-inflammatory activity of the tested compounds has been evaluated in comparison with their vehicle 
(control group) and naproxen. Table (4) explains the effect of tested compounds (Va-f) in comparison to control 
and naproxen. The tested compounds and the reference drug produced significant reduction of paw edema with 
respect to the effect of propylene glycol 50%v/v (control group). All tested compounds significantly limited the 
inflammation in paw edema, the onset of compound Vd started at time 60 min. while the remaining compounds 
and naproxen started at 120 min. Compounds Va-e exhibited potent anti-inflammatory effect than naproxen 
(50mg/kg, i.p.) at 180-240 min., while compound Vf  exhibited lower anti-inflammatory effect. However, the 
effect of all tested compound continued till the end of experiment with statistically significant (P<0.05) 
reduction in paw edema thickness as shown in Figure (2). 
 
4.1. Comparative Analysis 
The comparison explains that at 0-30 min. there are no differences among all groups. Compounds (Va-e) at time 
120-300 minutes show comparable effect to naproxen; however at interval 180-240 minutes show significantly 
higher effect. Although; compound Vf significantly limited the increase in paw edema in comparison to control 
group, but it is significantly lesser effect than naproxen and tested compounds (Va-e) at interval of 120-300 
minutes. 
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Table 4. The anti-inflammatory effect of control, Naproxen and compounds Va-f on egg-white induced paw            
edema in rats 
 
compounds 
Time (min) 
0 30 60 120 180 240 300 
P
a
w
 T
h
ic
k
n
es
s 
(m
m
) 
/ 
n
=
6
 
Control 4.40±0.08 5.43±0.10 6.18± 0.09 6.96±0.06 7.05±0.10 6.71±0.05 5.39±0.04 
Naproxen 4.36±0.07 5.48±0.08 6.11±0.10 5.71±0.08*a 5.54±0.09*a 5.27±0.10*a 4.73±0.05*a 
Va 4.37±0.10 5.41±0.05 5.97±0.09 5.66±0.04
*a 5.11±0.06*b 4.86±0.05*b 4.52±0.07*a 
Vb 4.40±0.06 5.40±0.10 5.99±0.04 5.68±0.07
*a 5.21±0.09*b 4.94±0.05*b 4.61±0.08*a 
Vc 4.38±0.05 5.42±0.04 6.06±0.06 5.73±0.10
*a 5.23±0.08*b 4.96±0.09*b 4.55±0.10*a 
Vd 4.35±0.04 5.41±0.10 5.82±0.07
* 5.51±0.06*a 5.12±0.05*b 4.88±0.08*b 4.53±0.10*a 
Ve 4.39±0.09 5.40±0.05 6.02±0.06 5.69±0.05
*a 5.22±0.07*b 4.93±0.04*b 4.59±0.10*a 
Vf 4.35±0.04 5.39±0.05 5.98±0.07 6.25±0.08
*b 5.85±0.10*c 5.57±0.06*c 5.05±0.09*b 
Non-identical superscripts (a, b&c) among different tested compounds are considered significantly different 
(P<0.05); *significantly different compared to control (P<0.05).Data are expressed in mm paw thickness as 
mean ± SEM. 
n= number of animals. Time (0) is the time of i.p. injection of naproxen and propylene glycol.  
Time (30) is the time of injection of egg white (induction of paw edema). 
 
 
Figure 2. Effect of naproxen, propylene glycol, compounds Va-f on egg-white induced paw edema in rats Results 
are expressed as mean ± SEM (n = 6 for each group) 
 
5. Conclusions 
Acute anti-inflammatory study using egg white induced edema model of inflammation revealed that the 
incorporation of 4-thiazolidinone pharmacophore into a naproxen maintained or enhanced it is anti-inflammatory 
activity.  
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